| Literature DB >> 35267966 |
Beata Olas1, Bartosz Skalski1.
Abstract
Numerous studies on the chemical composition of various organs of sea buckthorn (Elaeagnus rhamnoides (L.) A. Nelson) have found the plant to be a rich source of vitamins, phenolic compounds, amino acids, fatty acids, and micro- and macro-elements. Furthermore, other studies on preparations from various organs have found them to have significant anti-cancer, anti-ulcer, and hepatoprotective properties, as well as various antibacterial and antiviral activities. This paper reviews the current literature concerning the effect of different sea buckthorn preparations, i.e., extracts and fractions with various chemical contents, on hemostasis, and their positive role in the treatment and prevention of cardiovascular diseases. It also sheds new light on the mechanisms involved in their action on hemostasis both in vivo and in vitro. For these studies, biological materials, including blood platelets, plasma, and blood, were isolated from healthy subjects and those with cardiovascular risk factors. In addition, it describes the cardioprotective potential of commercial products from different organs of sea buckthorn.Entities:
Keywords: food product; hemostasis; platelets; safety; sea buckthorn
Mesh:
Substances:
Year: 2022 PMID: 35267966 PMCID: PMC8912734 DOI: 10.3390/nu14050991
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
The effect of consumption of sea buckthorn products on parameters of cardiovascular diseases in in vivo studies.
| Sea Buckthorn Product | Dose/Days | Subjects | Activity of Sea Buckthorn Product | References |
|---|---|---|---|---|
| Juice | 300 mL/day (56 days) | 30 Healthy people | Increase in HDL concentration | [ |
| Pulp and seed oil | Ten 500 mg capsules/day (42 days) | Healthy people | Inhibition of blood platelet aggregation | [ |
| Fruit puree | 30 g/day (90 days) | Healthy people | Increase in HDL concentration | [ |
| Seed oil | 5 mL/day (60 days) | Adult New Zealand white rabbits | Decrease in total cholesterol | [ |
| Dry fruits (powder) | 0.7 g/kg/day (60 days) | Stroke-prone rats | Decrease in total plasma cholesterol, triglyceride, heart rate, and blood pressure | [ |
| Pulp oil | 5, 10 and 20 mL/kg/day (30 days) | Wistar rats | Protecting against myocardial ischemia-reperfusion injury | [ |
| Total flavones extracted from seed residues | 150 mg/kg/day (42 days) | Chronic sucrose-fed rats | Antihypertensive action | [ |
| Tea from leaves | 1 or 5%/day (42 days) | Obese mice | Anti-visceral obesity potential | [ |
| Ethanolic extract of leaves | 500 or 1000 mg/kg | C57BL/6J mice | Anti-obesity potential | [ |
| Flavone (obtained from powdered leaves and whole fruits) | 75 mg/kg/day (42 or 84 days) | The apoE deficient mouse | Inhibition of macrophage foaming, inflammation, and vascular plaque formation | [ |
The effect of preparations from various organs of the sea buckthorn on selected elements of hemostasis (in vitro).
| Element of Hemostasis | Sea Buckthorn | Reference | ||
|---|---|---|---|---|
| Fruits | Leaves | Twigs | ||
| Inhibition of blood platelet adhesion to collagen and fibrinogen (using washed human blood platelets) | + | + | + | [ |
| Inhibition of blood platelet aggregation stimulated by thrombin (using washed human blood platelets) | ? | - | - | [ |
| Inhibition of blood platelet aggregation stimulated by ADP (using human platelet rich-plasma) | - | - | + | [ |
| Inhibition of blood platelet aggregation stimulated by collagen (using human platelet rich-plasma) | ? | - | - | [ |
| Inhibition of eicosanoid synthesis (using human washed blood platelets) | + | + | + | [ |
| Antioxidant activity (using human washed blood platelets and plasma) | + | + | + | [ |
| Reduction of GPIIb/IIIa exposition (using human whole blood) | + | + | + | [ |
| Reduction of thrombus formation (using human whole blood) | + | + | + | [ |
“?”—no studied; “+”—effect existing; “-”—no effect.
Figure 1Proposed mechanism of action of preparations from sea buckthorn on blood platelets. These preparations induce a decrease in reactive oxygen species (ROS) production. The decrease in intracellular ROS level may be accompanied by the recovery of phosphatase activity. Reactivated phosphatases may inhibit the activity of tyrosine kinases, and thus platelet aggregation (by inhibition of GPIIb/IIIa exposition). Sea buckthorn preparations also reduce the activity of cyclooxygenase (COX) and reduce arachidonic acid (AA) metabolism. However, the antiplatelet potential of the preparations is not dependent on the P2Y12 receptor.
Patents on cardiovascular activity of sea buckthorn (based on Singh et al. [61]).
| Number and Name of Patent | Chemical Content | Dose/Days | Subjects |
|---|---|---|---|
| A Chinese patent (CN103505484A) | Flavonoids, hydroxypropyl, and linoleic acid | 20 mg daily | Patients with coronary heart disease; angina pectoris |
| A Chinese patent (CN103505451A) | Isorhamnetin, quercetin, and kaempferol | 20 mg daily | Patients with coronary heart disease; angina pectoris |
| A Chinese patent (CN103505483A) | Fatty acids, phytosterol | - | Patients with hyperlipidemic |
| A Chinese patent (CN101612176A) | Tryptamine derivatives | - | Ischemic myocardial cells, in vitro |
| A Chinese patent (CN102058631A) | Flavonoids | 1, 2, 4 g/kg bw for 14 days | Sprague Dawley rat model |
Figure 2Sea buckthorn food products and their cardiovascular potential.